Thrombo-inflammation in Acute Neurovascular Diseases: Definition of New Therapeutic Targets (TARGETS)

Thrombo-inflammation Des Maladies Neurovascualires aiguës : définition de Nouvelles Cibles thérapeutiques (TARGETS)

Status

Not yet recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07354321

Enrollment

499

Registered

2026-01-21

Start date

2026-02-01

Completion date

2032-12-01

Last updated

2026-02-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Delayed Cerebral Ischemia After Subarachnoid Hemorrhage, Ischemic Stroke of Large or Medium Vessels

Keywords

delayed cerebral ischemia, subarachnoid hemorrhage, ischemic stroke

Brief summary

The objective of this observational study is to compare the relative concentrations of various thrombo-inflammatory markers at different follow-up time points in: * patients with or without delayed cerebral ischemia after subarachnoid hemorrhage, and * patients with or without rapid progression of necrotic volume after an ischemic stroke due to large- or medium-vessel occlusion in the anterior circulation. The main question this study aims to answer is: How do thrombo-inflammatory marker concentrations evolve over time and differ between patients? Researchers will compare patients with or without delayed cerebral ischemia after subarachnoid hemorrhage, as well as patients with or without rapid progression of necrotic volume following an ischemic stroke due to large- or medium-vessel occlusion in the anterior circulation, to determine whether there are differences in thrombo-inflammatory marker concentrations and in their evolution over time. Participants will undergo blood sampling at five different time points. In addition, participants will complete a Montreal Cognitive Assessment (MoCA) questionnaire during the 3-month follow-up visit.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Patients aged 18 years or older * Admitted within 8 hours of an acute ischemic stroke (AIS) due to large-vessel occlusion (LVO) or medium-vessel occlusion (MeVO) of the anterior circulation, with a NIHSS (National Institutes of Health Stroke Scale) score \> 5 (M1, M2, M3, A1, A2, A3, P1, P2) * Or admitted within 36 hours of acute symptoms related to aneurysmal subarachnoid hemorrhage (SAH)

Exclusion criteria

* Patients with pre-existing functional and/or cognitive disability (modified Rankin Scale, mRS \> 1) * Patients under legal protection or guardianship * Patients with secondary hemorrhagic transformation of an acute ischemic stroke Patients with acute ischemic stroke and NIHSS \> 5 without LVO or MeVO of the anterior circulation on imaging will be secondarily excluded. Perfusion imaging will not be performed as part of the research protocol. Excluded patients will be replaced.

Design outcomes

Primary

Measure	Time frame	Description
Investigation of changes in thrombo-inflammatory marker concentrations between patients and over time.	From enrollment to Month 3 visit	Investigation of changes in thrombo-inflammatory marker concentrations between patients and over time.

Contacts

CONTACTFrançois Delvoye, MD, PhD

fdelvoye@chuliege.be04/3236630

CONTACTSimon Detriche, PhD

sdetriche@chuliege.be043236684

Outcome results